Table 1.
Baseline characteristics.
| Baseline characteristics | Number | Percentage |
|---|---|---|
| Median age | 60 | – |
| Male | 37 | 80% |
| ECOG performance status | ||
| 0 | 20 | 44% |
| 1 | 23 | 50% |
| 2 | 1 | 2% |
| Unknown | 2 | 4% |
| Cancer subtype | ||
| Melanoma | 33 | 72% |
| Urothelial carcinoma | 4 | 9% |
| Renal cell carcinoma | 2 | 4% |
| Mesothelioma | 2 | 4% |
| Hepatocellular carcinoma | 2 | 4% |
| Non-small cell lung cancer | 1 | 2% |
| Gastric cancer | 1 | 2% |
| Glioblastoma | 1 | 2% |
| AJCC stage | ||
| I | 1 | 2% |
| II | 1 | 2% |
| III | 3 | 7% |
| IV | 41 | 89% |
| Underlying condition | ||
| Solid organ transplant | 6 | 13% |
| HIV | 12 | 6% |
| Hepatitis B | 14 | 30% |
| Hepatitis C | 14 | 30% |
| Immunotherapy | ||
| Pembrolizumab | 21 | 46% |
| Nivolumab | 12 | 26% |
| Atezolizumab | 2 | 4% |
| Sequential PD-1 then CTLA-4 | 7 | 15% |
| Concurrent PD-1 and CTLA-4 | 4 | 9% |
| Total | 46 |
ECOG: Eastern Cooperative Oncology Group; AJCC: American Joint Committee on Cancer.